3
March 12, 2025
Today’s health care methods
Combined GLP-1 Drug: A Texas State Judge denies PI motion that the shortage of tilzepatide will be resolved and FDA’s declaration’s request for stay. Plaintiffs of appeal
On March 5, 2025, one US District Court explicitly ruled in favour of the Food and Drug Administration (FDA). Al. v. US Food and Drug Manager, and others. , 4:24-CV-0953-P, Slip Op. , 2025 WL 746028, *15 (Nd Tex. Mar.5, 2025). (2) Pending stay for review proceedings was resolved in response to the FDA’s declaration that the shortage of diabetes and weight loss tilzepatide products has been resolved.
